Literature DB >> 10536249

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.

P P Le Brun1, A H de Boer, D Gjaltema, P Hagedoorn, H G Heijerman, H W Frijlink.   

Abstract

Forteen commercially available jet and ultrasonic nebulizers were investigated with the aim to select the most suitable type of apparatus for the inhalation of a 10% tobramycin solution. Two different techniques for measurement of particle size distribution were evaluated: laser diffraction and cascade impactor analysis. The final selection of the nebulizers is based on particle size distribution, output and stable performance during nebulization. All 14 nebulizers (eight jet and six ultrasonic) were filled with a solution of 10% m/v tobramycin (as sulphate) in water. The volume in the tested devices ranged from 4.5 to 10 ml (=450-1000 mg tobramycin) in accordance with the prescribed usage by the suppliers. The nebulizers were connected with a special designed adapter to a laser diffraction analyser in order to measure particle size distribution of the aerosol. Inhalation was simulated with a static flow of 40 l/min. The particle size distribution (expressed as X(10), X(50), and X(90)) was determined after 10 s, 1.5, 3, 4.5, 6, 9 and 12 min of nebulization. Furthermore, the tobramycin solutions were assayed for tobramycin content before and after nebulization. For all nebulizers, the mean particle size distribution, depicted as X(50), was within the range of 1-5 mm. There were no relevant differences between the nebulizers in concentration or particle size distribution during nebulization. The output of the nebulizers is a result of both nebulization and evaporation. The output, expressed as volume of tobramycin solution, ranged from 0.06 to 0.50 ml/min. The output of tobramycin ranged from 1.2 to 39.5 mg/min. For clinical practice 300-600 mg have to be nebulized within 20-30 min. It was concluded that only three jet nebulizers [Porta-Neb Sidestream (PNS), Porta-Neb Ventstream (PNV) and Pariboy Pari LC+ (PLC)] have a reasonable output and an acceptable particle size distribution for the administration of a 10% tobramycin solution in the therapeutic dosage range.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536249     DOI: 10.1016/s0378-5173(99)00251-3

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.

Authors:  John Denyer; Ivan Prince; Emma Dixon; Penny Agent; Jennifer Pryor; Margaret Hodson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

2.  Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

Authors:  Gerard Lenoir; Yuriy Genadievich Antypkin; Angelo Miano; Paolo Moretti; Maurizio Zanda; Guido Varoli; Pier Alessandro Monici Preti; Nikolay Leonidovich Aryayev
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.

Authors:  Emma Vázquez-Espinosa; Rosa María Girón; Rosa Mar Gómez-Punter; Elena García-Castillo; Claudia Valenzuela; Carolina Cisneros; Enrique Zamora; F Javier García-Pérez; Julio Ancochea
Journal:  Ther Clin Risk Manag       Date:  2015-03-12       Impact factor: 2.423

Review 4.  Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

Authors:  John Lam; Steven Vaughan; Michael D Parkins
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-11-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.